Search our Database of Scientific Publications and Authors

I’m looking for a

    3646 results match your criteria Oral Malignant Melanoma

    1 OF 73

    Unusual presentation of renal cell carcinoma: A rare case report.
    J Lab Physicians 2018 Apr-Jun;10(2):241-244
    Department of Pathology, Dr. Ram Manohar Lohia Hospital, PGIMER, New Delhi, India.
    Cutaneous and intraoral metastasis from any malignancy is not common. Cutaneous spread is usually noted in 5%-10% of high-grade malignancies, as in carcinoma breast, lung, colon, ovary, and malignant melanoma. Only 4. Read More

    Evaluation of biodistribution of sulforaphane after administration of oral broccoli sprout extract in melanoma patients with multiple atypical nevi.
    Cancer Prev Res (Phila) 2018 Apr 24. Epub 2018 Apr 24.
    Division of Hematology/Oncology, University of Pittsburgh School of Medicine
    Broccoli sprout extract containing sulforaphane (BSE-SFN) has been shown to inhibit ultraviolet radiation-induced damage and tumor progression in skin. This study evaluated the toxicity and potential effects of oral BSE-SFN at three dosages. Seventeen patients who each had at least 2 atypical nevi and a prior history of melanoma were randomly allocated to 50, 100, or 200 µmol oral BSE-SFN daily for 28 days. Read More

    Incidence of complications in dermatological surgery of melanoma and non-melanoma skin cancer in patients with multiple comorbidity and/or antiplatelet-anticoagulants. Five year experience in our Hospital.
    Cir Cir 2018 ;86(1):20-28
    Departamento de Dermatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
    Introduction: Surgery is performed more frequently now at days, due to the increasing incidence of melanoma and no-melanoma skin cancer. There are different opinions among dermatologic surgeons between to continue or discontinue antithrombotic therapy prior to the procedure, which increases the risk of thromboembolic events. Prophylaxis with oral antibiotics in the postsurgical period is controversial. Read More

    Orbital Floor Reconstruction: 3-Dimensional Analysis Shows Comparable Morphology of Scapular and Iliac Crest Bone Grafts.
    J Oral Maxillofac Surg 2018 Mar 28. Epub 2018 Mar 28.
    Professor/Head, Division of Head and Neck Oncology, Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre and Guided Therapeutics (GTx) Program, University of Toronto, Toronto, Ontario, Canada.
    Purpose: Current nonvascular osseous reconstructive options for reconstruction of the orbital floor after maxillectomy include options such as scapular tip and iliac crest bone grafts. The aim of this study was to determine whether these donor sites were morphologically comparable with the orbital floor.

    Materials And Methods: A retrospective cross-sectional study design was selected. Read More

    Management of Chronic Hypotony following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.
    Ocul Immunol Inflamm 2018 Apr 19:1-4. Epub 2018 Apr 19.
    b Department of Ophthalmology , Warrington & Holton Hospitals NHS Foundation Trust, Lovely Lane , Warrington , UK.
    Purpose: To describe the presentation and management of severe ocular adverse events following treatment with pembrolizumab for cutaneous metastatic melanoma.

    Methods: Interventional case report.

    Results: A 73-year-old Caucasian man receiving pembrolizumab treatment for metastatic melanoma presented with panuveitis and subsequent profound hypotony, choroidal effusions, and optic disk swelling bilaterally. Read More

    UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response.
    Oxid Med Cell Longev 2018 18;2018:9742154. Epub 2018 Feb 18.
    Key Laboratory of Biorheological Science and Technology, Ministry of Education, Chongqing University, Chongqing 400044, China.
    Brusatol (BR) is a potent inhibitor of Nrf2, a transcription factor that is highly expressed in cancer tissues and confers chemoresistance. UVA-generated reactive oxygen species (ROS) can damage both normal and cancer cells and may be of potential use in phototherapy. In order to provide an alternative method to treat the aggressive melanoma, we sought to investigate whether low-dose UVA with BR is more effective in eliminating melanoma cells than the respective single treatments. Read More

    Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
    Lancet Respir Med 2018 Apr 12. Epub 2018 Apr 12.
    Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
    Background: An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations.

    Methods: We did a multicentre, biomarker-driven, single-drug, non-randomised, open-label, two-stage phase 2 trial (European Organisation for Research and Treatment of Cancer 90101 CREATE) at 13 study sites (five university hospitals and eight specialty clinics) in eight European countries (Belgium, France, Germany, Italy, Netherlands, Poland, Slovakia, and the UK). Read More

    Ultrasound Promoted Green Synthesis, Docking study of Indole Spliced Thiadiazole, α-amino phosphonates as Anticancer Agents and Anti-tyrosinase Agents.
    Anticancer Agents Med Chem 2018 Apr 17. Epub 2018 Apr 17.
    Shreeyash Institute of Pharmacy - Department of Pharmaceutical Chemistry Aurangabad. India.
    In this work, a new series of diethyl ((1H-indole-3-yl)((5-phenyl-1,3,4-thiadiazole-2- yl)amino)methyl)phosphonate derivatives 6(a-j) were designed and synthesized in Ultrasound by green protocol using Kabachnik-Fields reaction. The structures of the synthesized compounds were confirmed by spectral analysis such as elemental analyses, IR, 1H NMR, 13C NMR, 31P NMR and mass spectra. The synthesized compounds 6(a-j) were appraised for their in vitro anticancer activity against human cancer cell lines such as SK-MEL-2 (melanoma), IMR-32 (Neuroblastoma), HT-29(Colon) and also on normal murine embryonic fibroblast NIH/3T3 by Sulforhodamine B (SRB) assay, using Adriamycin as a standard drug. Read More

    Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance).
    Oncologist 2018 Apr 17. Epub 2018 Apr 17.
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
    Lessons Learned: Everolimus does not have sufficient activity to justify its use as single agent in metastatic melanoma.Patients treated with 10 mg per day dose were most likely to require dose reductions.Everolimus appeared to reduce the numbers of regulatory T cells in approximately half of the treated patients; unfortunately, these effects were not correlated with clinical outcomes. Read More

    The importance of melanoma inhibitory activity gene family in the tumor progression of oral cancer.
    Pathol Int 2018 Apr 14. Epub 2018 Apr 14.
    Department of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Japan.
    Oral squamous cell carcinoma has a high potential for locoregional invasion and nodal metastasis. Consequently, early detection of such malignancies is of immense importance. The melanoma inhibitory activity (MIA) gene family comprises MIA, MIA2, transport and Golgi organization protein 1 (TANGO), and otoraplin (OTOR). Read More

    Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
    BMC Cancer 2018 Apr 12;18(1):413. Epub 2018 Apr 12.
    Cellworks Group, Inc., 2033 Gateway Place Suite 500, San Jose, CA, 95110, USA.
    It has been highlighted that in the original manuscript [1] Table S3 'An example of the predictive computational modeling process. Specific details on an annexure section of the PD-L1 pathway show the step-by-step reactions, mechanisms, and reaction equations that occur. Such reactions also occurred in all of the other pathways' was omitted and did not appear in the Additional files and that the Additional files were miss-numbered thereafter. Read More

    Pigmented squamous cell carcinoma: case report and importance of differential diagnosis.
    An Bras Dermatol 2018 Jan-Feb;93(1):96-98
    Division of Surgery at Fundação Alfredo da Matta (FUAM) - Manaus (AM), Brazil.
    A few cases of pigmented squamous cell carcinoma affecting the skin and the ocular and oral mucosa of the elderly have been described in the literature. The disease manifests itself as papular and nodular erythematous or pigmented lesions. The main clinical differential diagnoses are pigmented basal cell carcinoma and melanoma. Read More

    Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response.
    Gastroenterology 2018 Apr 6. Epub 2018 Apr 6.
    Department of Surgery at Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, FL, 33136, USA. Electronic address:
    We studied the effects of gut microbiome depletion by oral antibiotics on tumor growth in subcutaneous and liver metastases model of pancreatic cancer, colon cancer and melanoma. Gut microbiome depletion significantly reduced tumor burden in all the models tested. However, depletion of gut microbiome did not reduce tumor growth in Rag1-knockout mice, which lack mature T and B cells. Read More

    Phosphoproteome profiling provides insight into the mechanism of action for carvedilol-mediated cancer prevention.
    Mol Carcinog 2018 Apr 6. Epub 2018 Apr 6.
    Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California.
    Recent studies suggest that the β-blocker drug carvedilol prevents skin carcinogenesis but the mechanism is unknown. Carvedilol is one of a few β-blockers identified as biased agonist based on an ability to promote β-arrestin-mediated processes such as ERK phosphorylation. To understand the role of phosphoproteomic signaling in carvedilol's anticancer activity, the mouse epidermal JB6 P+ cells treated with EGF, carvedilol, or their combination were analyzed using the Phospho Explorer Antibody Array containing 1318 site-specific and phospho-specific antibodies of over 30 signaling pathways. Read More

    The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells.
    Mol Oncol 2018 Apr 6. Epub 2018 Apr 6.
    Daniel Swarovski Research Laboratory, Department of Visceral-, Transplant- and Thoracic Surgery, Medical University of Innsbruck (MUI), 6020, Innsbruck, Austria.
    Metabolic reprogramming, as exemplified by the shift from oxidative phosphorylation to glycolysis, is a common feature of transformed cells. In many tumors, altered metabolism is also reflected in increased ROS levels, which contribute to proliferation and survival signaling. However, despite high ROS levels, cancer cells can be efficiently killed by further increasing ROS production. Read More

    Treatment of Canine Oral Melanoma with Nanotechnology-Based Immunotherapy and Radiation.
    Mol Pharm 2018 Apr 12. Epub 2018 Apr 12.
    Geisel School of Medicine at Dartmouth , Hanover , New Hampshire 03755 , United States.
    The presence and benefit of a radiation therapy-associated immune reaction is of great interest as the overall interest in cancer immunotherapy expands. The pathological assessment of irradiated tumors rarely demonstrates consistent immune or inflammatory response. More recent information, primarily associated with the "abscopal effect", suggests a subtle radiation-based systemic immune response may be more common and have more therapeutic potential than previously believed. Read More

    Immunohistochemical Expression of FXR1 in Canine Normal Tissues and Melanomas.
    J Histochem Cytochem 2018 Apr 1:22155418766292. Epub 2018 Apr 1.
    Department of Veterinary Medicine, Università degli Studi di Milano, Milan (MI), Italy.
    Fragile X mental retardation-related protein 1 (FXR1) is a cytoplasmic RNA-binding protein highly conserved among vertebrates. It has been studied for its role in muscle development, inflammation, and tumorigenesis, being related, for example, to metastasizing behavior in human and canine uveal melanoma. Anti-FXR1 antibodies have never been validated in the canine species. Read More

    Exosomal tetraspanins as regulators of cancer progression and metastasis and novel diagnostic markers.
    Asia Pac J Clin Oncol 2018 Mar 25. Epub 2018 Mar 25.
    Department of Biochemistry, Cancer Biology Lab, Institute of Science, Gandhi Institute of Technology and Management (GITAM) (Deemed to be university), Visakhapatnam, India.
    Exosomes are cell-cell communicators emerging as a new paradigm for noninvasive diagnosis and prognosis of treatment response. Exosomal tetraspanin proteins like CD63, CD9 and CD81 play a critical role in sorting, selective recruitment of biomolecules, target selection, cell-specific entry, capturing, angiogenesis and vasculogenesis. These tetraspanins are being used as markers for oral, colorectal and colon cancers and glioblastoma. Read More

    Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Lancet Oncol 2018 Mar 21. Epub 2018 Mar 21.
    Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
    Background: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAF-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAF-mutant melanoma.

    Methods: COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries. Read More

    The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
    Eur J Cancer 2018 May 20;94:156-167. Epub 2018 Mar 20.
    Department of Oncology, University College London Hospitals NHS Trust, London, UK.
    Background: Alveolar rhabdomyosarcomas (ARMSs) can harbour MET and anaplastic lymphoma kinase (ALK) alterations. We prospectively assessed crizotinib in patients with advanced/metastatic ARMS.

    Methods: Eligible patients with a central diagnosis of ARMS received oral crizotinib 250 mg twice daily. Read More

    Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.
    Immunotherapy 2018 Mar 22. Epub 2018 Mar 22.
    Medical Oncology Unit, St Salvatore Hospital, Department of Biotechnological & Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
    Aim: Tumors related to hereditary susceptibility seem to have an immunosensitive phenotype.

    Materials & Methods: We conducted a multicenter retrospective study, to investigate if family history of cancer, multiple neoplasms and early onset of cancer could be related to clinical outcomes of anti-PD-1/PD-L1 therapy. Activity and efficacy data of 211 advanced cancer patients (kidney, non-small-cell lung cancer, melanoma, urothelium, colorectal and HeN), treated at seven Italian centers with anti-PD-1/PD-L1 agents, were analyzed. Read More

    Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody LMab-4.
    Biochem Biophys Rep 2018 Mar 6;13:123-128. Epub 2018 Feb 6.
    Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
    Programmed cell death-ligand 1 (PD-L1), which is a ligand of programmed cell death-1 (PD-1), is a type I transmembrane glycoprotein that is expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. There is a strong correlation between human PD-L1 (hPD-L1) expression on tumor cells and negative prognosis in cancer patients. In this study, we produced a novel anti-hPD-L1 monoclonal antibody (mAb), LMab-4 (IgG, kappa), using cell-based immunization and screening (CBIS) method and investigated hPD-L1 expression in oral cancers. Read More

    MAGE-A9 in head and neck cancer: Prognostic value and preclinical findings in the context of irradiation.
    Mol Clin Oncol 2018 Mar 19;8(3):513-519. Epub 2018 Jan 19.
    Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, D-97070 Würzburg, Germany.
    Radiotherapy alone, or as an addition to surgery is important for the treatment of head and neck squamous cell carcinoma (HNSCC). In addition to their expression in germ cells, melanoma associated antigens-A (MAGE-A) are only expressed in malignant tissue. Notably, there is a known correlation between MAGE-A9 expression and poor prognosis in HNSCC patients. Read More

    EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.
    J Control Release 2018 May 14;277:48-56. Epub 2018 Mar 14.
    Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy; MediaPharma s.r.l., Via della Colonnetta 50/A, Chieti, Italy. Electronic address:
    Cutaneous melanoma is one of the cancers with the fastest rising incidence and in its advanced metastatic form is a highly lethal disease. Despite the recent approval of several new drugs, the 5-year overall survival rate for advanced cutaneous melanoma is still below 20% and therefore, the development of novel treatments remains a primary need. Antibody-Drug Conjugates are an emerging novel class of anticancer agents, whose preclinical and clinical development has recently seen a remarkable increase in different tumors, including melanoma. Read More

    Rural-Urban Disparities in Stage of Diagnosis Among Cancers With Preventive Opportunities.
    Am J Prev Med 2018 May 15;54(5):688-698. Epub 2018 Mar 15.
    Office of Population Science and Policy, Southern Illinois University School of Medicine, Springfield, Illinois.
    Introduction: Despite having lower overall incidence rates, rural populations tend to have higher cancer mortality rates. Rural populations often have higher rates of cancers with primary and secondary prevention modalities. However, there is limited research on rural-urban differences in incidence by stage. Read More

    Metastases to the parotid gland - A review of the clinicopathological evolution, molecular mechanisms and management.
    Surg Oncol 2018 Mar 2;27(1):44-53. Epub 2017 Dec 2.
    Sydney Head and Neck Cancer Institute, Department of Head and Neck Surgery, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia; Central Clinical School, University of Sydney, New south Wales, Australia.
    Metastases to the parotid gland are the commonest cause of parotid malignancies in many regions of the world including Australia. The most common etiology of these metastases is head and neck cutaneous squamous cell carcinoma (HNcSCC) followed by melanoma of the head and neck. This article focuses on the management of the aforementioned pathologies including Merkel cell carcinoma (MCC). Read More

    Multidisciplinary therapy for metastatic primary malignant melanoma of the esophagus: A case report.
    Mol Clin Oncol 2018 Apr 13;8(4):533-538. Epub 2018 Feb 13.
    Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
    Standard treatment strategies have not yet been established for primary malignant melanoma of the esophagus (PMME), and far much less for recurrent disease. There are no reports of anti-programmed death-1 antibody treatment of recurrent PMME. A 60-year-old Japanese man was diagnosed with a primary malignant melanoma in the lower esophagus. Read More

    Acral Spitz Nevi: A Clinicopathologic Study of 50 Cases With Immunohistochemical Analysis of P16 and P21 Expression.
    Am J Surg Pathol 2018 Mar 13. Epub 2018 Mar 13.
    Department of Pathology, Western General Hospital and The University of Edinburgh, Edinburgh, UK.
    Spitz nevi on acral sites are rare and poorly documented. The combination of Spitzoid cytomorphology and atypical architectural features of the junctional component may lead to an erroneous diagnosis of melanoma. To study the clinicopthologic and immunohistochemical features, 50 Spitz nevi localized on the distal extremities were retrieved from departmental files. Read More

    Primary sinonasal mucosal melanoma simulated as cystic lesions: a case report.
    J Korean Assoc Oral Maxillofac Surg 2018 Feb 26;44(1):29-33. Epub 2018 Feb 26.
    Department of Oral Pathology, School of Dentistry, Seoul National University, Seoul, Korea.
    Sinonasal mucosal melanoma (SNMM) in the maxillary sinus is a rare disease condition. Compared to oral mucosal melanoma, SNMM has a bulky, exophytic, and polypoid appearance, is weakly pigmented, and associated with unspecific symptoms. Due to these features, SNMM in the maxillary sinus has been misdiagnosed as nasal polyps and chronic sinusitis. Read More

    Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
    J Clin Oncol 2018 Apr 12;36(12):1232-1239. Epub 2018 Mar 12.
    Richard D. Carvajal and Gary K. Schwartz, Columbia University Medical Center; Paul B. Chapman and Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center, New York, NY; Sophie Piperno-Neumann and Manuel J. Rodrigues, Institut Curie, Paris; Lauris Gastaud, Centre Antoine-Lacassagne, Nice, France; Ellen Kapiteijn, Leiden University Medical Center, Leiden, the Netherlands; Stephen Frank, Hebrew University Hadassah Medical School - The Sharett Institute of Oncology, Jerusalem; Jacob Schachter, Sheba Medical Center at Tel Hashomer, and Tel-Aviv University Medical School, Tel Aviv, Israel; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Josep M. Piulats, Institut Catala d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Pascal Wolter, University Hospitals Leuven, Leuven, Belgium; Veronique Cocquyt, Ghent University Hospital, Ghent, Belgium; Bartosz Chmielowski, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; T.R. Jeffry Evans, University of Glasgow, Glasgow; Delyth Clemett, Shirley Spratt, Susan Lovick, and Elaine Kilgour, AstraZeneca, Macclesfield; Dana Ghiorghiu and Gabriella Mariani, AstraZeneca, Cambridge; Paul Nathan, Mt Vernon Cancer Centre, Northwood, United Kingdom; Gerald Linette, Washington University School of Medicine, St Louis, MO; Carola Berking, University Hospital of Munich, Munich, Germany; Peter Barker, AstraZeneca, Gaithersburg, MD; and Zhongwu Lai, AstraZeneca, Waltham, MA.
    Purpose Uveal melanoma is the most common primary intraocular malignancy in adults with no effective systemic treatment option in the metastatic setting. Selumetinib (AZD6244, ARRY-142886) is an oral, potent, and selective MEK1/2 inhibitor with a short half-life, which demonstrated single-agent activity in patients with metastatic uveal melanoma in a randomized phase II trial. Methods The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial ( ClinicalTrial. Read More

    A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects.
    Case Rep Dermatol 2018 Jan-Apr;10(1):1-6. Epub 2018 Jan 18.
    Department of Dermatology, Division of Medical Sciences, University of Fukui, Fukui, Japan.
    Immune checkpoint inhibitors, such as ipilimumab and nivolumab, reverse the imbalance of antitumor self-tolerance and enhance T-cell responses. Currently, ipilimumab and nivolumab have a reported therapeutic impact on unresectable or metastatic melanomas; however, they also induce immune-related adverse events (irAEs). Ipilimumab-induced cutaneous irAEs are mostly low grade and manageable, although all-grade rash may occur in approximately 45% of all patients. Read More

    Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights.
    Redox Biol 2018 Jun 1;16:169-178. Epub 2018 Mar 1.
    Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784, Greece. Electronic address:
    Natural products are characterized by extreme structural diversity and thus they offer a unique source for the identification of novel anti-tumor agents. Herein, we report that the herbal substance acteoside being isolated by advanced phytochemical methods from Lippia citriodora leaves showed enhanced cytotoxicity against metastatic tumor cells; acted in synergy with various cytotoxic agents and it sensitized chemoresistant cancer cells. Acteoside was not toxic in physiological cellular contexts, while it increased oxidative load, affected the activity of proteostatic modules and suppressed matrix metalloproteinases in tumor cell lines. Read More

    Combined laparoscopic abdomino-endoscopic perineal total mesorectal excision for anorectal malignant melanoma: A case report.
    Int J Surg Case Rep 2018 22;44:135-138. Epub 2018 Feb 22.
    Department of Surgery, Institute of Gastroenterology, Kawasaki Saiwai Hospital, Kawasaki, Japan.
    Introduction: This report presents a case of anorectal malignant melanoma treated with combined laparoscopic abdomino-endoscopic perineal total mesorectal excision.

    Presentation Of Case: An 82-year-old female presented with hematochezia. Colonoscopy revealed a 5-cm tumor in the anorectal junction, and biopsy specimen showed malignant melanoma. Read More

    Cutaneous horn: A mask to underlying malignancy.
    J Oral Maxillofac Pathol 2018 Jan;22(Suppl 1):S87-S90
    Department of Oral Pathology, Manubhai Patel Dental College, Vadodara, Gujarat, India.
    Cutaneous horns () are uncommon lesions consisting of keratotic material resembling that of an animal horn. It is a conical- or cylindrical-shaped excessive hyperkeratosis of variable size ranging from few millimeters to several centimeters with a variable in size and shape, such as cylindrical, conical, pointed, transversely or longitudinally corrugated, or curved like a ram's horn. The lesions typically occur in sun-exposed areas, particularly the face, ear, nose, forearms and dorsum of hands. Read More

    Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
    BMC Cancer 2018 02 27;18(1):225. Epub 2018 Feb 27.
    Cellworks Group, Inc., 2033 Gateway Place Suite 500, San Jose, CA, 95110, USA.
    Background: Programmed Death Ligand 1 (PD-L1) is a co-stimulatory and immune checkpoint protein. PD-L1 expression in non-small cell lung cancers (NSCLC) is a hallmark of adaptive resistance and its expression is often used to predict the outcome of Programmed Death 1 (PD-1) and PD-L1 immunotherapy treatments. However, clinical benefits do not occur in all patients and new approaches are needed to assist in selecting patients for PD-1 or PD-L1 immunotherapies. Read More

    Primary Oral Mucosal Melanomas - Two Case Reports and Comprehensive Literature Review.
    Acta Clin Croat 2017 Jun;56(2):323-330
    Private Dental Surgery, Sarajevo, Bosnia and Herzegovina.
    Oral melanoma (OM) occurs from activated or genetically altered epidermal melanocytes. There is no scientific evidence that OM can be linked to physical, chemical and thermal irritation, or to other risk factors of the oral cavity. According to fi gures from various countries, OM accounts for 0. Read More

    Arthrospira Platensis - Potential in Dermatology and Beyond.
    Open Access Maced J Med Sci 2018 Jan 10;6(1):176-180. Epub 2018 Jan 10.
    Department of Dermatology, Venereology and Dermatologic Surgery, Medical Institute of Ministry of Interior, Sofia, Bulgaria.
    The search for natural products with benefits for health in general and of potential for treating human disease has gained wider interest world-wide. Here, we analyse current data on the microalga Arthrospira platensis (AP), that has been used in nutrition since ancient times in Fare East and African communities, for medical purposes with a focus on dermatology. Extracts of AP have been investigated in vitro and in vivo. Read More

    Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Lancet Oncol 2018 Apr 21;19(4):510-520. Epub 2018 Feb 21.
    Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.
    Background: Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC-III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAF mutation-positive melanoma.

    Methods: BRIM8 was a phase 3, international, double-blind, randomised, placebo-controlled study that enrolled 498 adults (aged ≥18 years) with histologically confirmed stage IIC-IIIA-IIIB (cohort 1) or stage IIIC (cohort 2) BRAF mutation-positive melanoma that was fully resected. Read More

    Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
    Dermatol Online J 2017 Oct 15;23(10). Epub 2017 Oct 15.
    Department of Dermatology, Dermatologist, Hospital Universitario Doctor Peset, Valencia, Spain.
    Vemurafenib ha probado ser una herramienta útil en el tratamiento de melanoma metastásico con mutación BRAF-V600E. Los efectos adversos incluyen artralgias, fatiga y toxicidad cutánea, siendo infrecuente la paniculitis. Presentamos el caso de una paciente de 43 años con melanoma metastásico que desarrolla lesiones subcutáneas dolorosas en miembros inferiores y superiores, asociadas a clínica sistémica después de 2 semanas de inicio de tratamiento con Vemurafenib + Cobimetinib. Read More

    Lichen planus: molecular pathway and clinical implications in oral disorders.
    J Biol Regul Homeost Agents 2018 Jan-Feb;32(2 Suppl. 1):135-138
    Department of Biochemistry, Biophysics and General Pathology, University of Campania “Luigi Vanvitelli”, Naples, Italy.
    Stem cells play a role in many mucosal disorders characterised by abnormal proliferation and differentiation of keratinocytes, such as oral lichen planus (OLP). In OLP there were changes in stem cell markers as component of integrin complexes α6 and β1 integrin increased along with increase of melanoma-associated chondroitin sulphate proteoglycan (MCSP) and decreased of notch1 (N1) and keratin 15 (K15). Stem cell marker expression may be altered by pathological signalling in these lesions. Read More

    Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma: A Case Report.
    Intern Med 2018 Feb 9. Epub 2018 Feb 9.
    Department of Gastroenterology, Toyonaka Municipal Hospital, Japan.
    A 42-year-old man was diagnosed with cStage IIIb malignant melanoma and underwent resection. After interferon-beta therapy, 18-fluorodeoxyglucose-positron emission tomography/computed tomography (F-FDG PET/CT) showed multiple lung metastases, and he received nivolumab (2 mg/kg) every 3 weeks, resulting in a total of 17 cycles. After treatment, F-FDG PET/CT showed a significant decrease in the size of the metastases, but he had a Grade 4 ALT elevation. Read More

    Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    J Immunother Cancer 2018 Feb 12;6(1):13. Epub 2018 Feb 12.
    Hematology/Oncology, Norris cotton Cancer Center, One Medical Center Dr., Lebanon, NH, 03756, USA.
    Background: Uveal melanoma accounts for 85% of the ocular melanomas and has an increased risk of hematogenous spread, most commonly to the liver. After curative intent therapy like surgery and radiation, fifty percent of patients present with distant metastasis. Metastatic uveal melanoma (MUM) does not harbor typically targetable mutations, e. Read More

    Longitudinal clinicopathologic data of the progression of oral mucosal melanoma-report of 2 cases and literature review.
    Oral Surg Oral Med Oral Pathol Oral Radiol 2017 Dec 28. Epub 2017 Dec 28.
    Diagnostic Sciences, TAMU College of Dentistry, Dallas, TX, USA.
    Oral mucosal melanoma (OMM) is notorious for having a poor prognosis. Recognition of the early features of OMM by both clinicians and pathologists can play an important role in improving survival. Therefore, the purpose of this report is to increase awareness of the early features of OMM, by presenting 2 cases with longitudinal clinical and histopathologic documentation showing progression of OMM from a deceptively bland premalignant (noninvasive) oral melanocytic lesion (POML). Read More

    Second Malignancies after Hematopoietic Stem Cell Transplantation.
    Curr Treat Options Oncol 2018 Feb 8;19(2). Epub 2018 Feb 8.
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel.
    Opinion Statement: Second malignancies are a rare but well-defined late complication after autologous and allogeneic hematopoietic stem-cell transplantation (SCT). Solid malignancies occur in up to 15% of patients 15 years after SCT with myeloablative conditioning, with no plateau in the incidence rates. They are responsible for 5-10% of late deaths after SCT. Read More

    1 OF 73